Neurogene (NGNE) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Neurogene (NGNE) is Moderate Underperform.

The composite score behind that read is -0.21, weighing +0.17 of bullish evidence against -0.29 bearish.

Neurogene last closed at $26.47, +3.20% on the session.

Against the IVW growth benchmark the position is +2.28% over the forecast window.

The read is built from 12 underlying insights — 3 bullish and 9 bearish.

Agreement across those insights is 75%.

14 graded predictions for NGNE so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Neurogene in the 19th percentile on return on equity, where 100 is best.

Neurogene is classified under Health Care / Biotechnology, with a market capitalisation of $513.28M.

StockMap tracks Neurogene as the 166th largest of the 344 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 180 Moderate Underperform, 152 Neutral, 11 Strong Underperform and 1 Moderate Outperform.

On that composite Neurogene ranks 171st of 344 in the group, against a group median of -0.21.